Domenico Ribatti
University of Bari
965 Papers
6.1K Citations
Domenico Ribatti is an academic researcher from University of Bari. The author has contributed to research in topics: Angiogenesis & Biology. The author has an hindex of 96, co-authored 913 publications. Previous affiliations of Domenico Ribatti include University of Genoa & National Institutes of Health.
Chat about Author
Papers
The discovery of angiogenic factors: a historical review.
TL;DR: A historical account of the relevant literature concerning the discovery of the best-characterized angiogenic factors is offered.
•Journal Article
Interplay between mast cells and lymphatic vessels in different molecular types of breast cancer.
TL;DR: The results strongly support that mast cells in the tumor microenvironment are keyplayers, involved in the development of tumor lymphatic vessels for some molecular subtypes of breast cancer.
Intussusceptive microvascular growth in tumors
Domenico Ribatti,Valentin Djonov +1 more
TL;DR: Interestingly, an angiogenic switch from sprouting to intussusceptive angiogenesis occurs after treatment withAngiogenesis inhibitors and may be considered as a tumor-protective adaptative response.
Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo
Domenico Ribatti,Marco Presta,Marco Presta,Angelo Vacca,Angelo Vacca,Roberto Ria,Roberto Ria,Roberta Giuliani,Roberta Giuliani,Patrizia Dell'Era,Patrizia Dell'Era,Beatrice Nico,Beatrice Nico,Luisa Roncali,Luisa Roncali,Franco Dammacco,Franco Dammacco +16 more
TL;DR: The ability of Epo to interact directly with endothelial cells and to elicit an angiogenic response in vitro and in vivo is demonstrated and thus acts as a bona fide directAngiogenic factor.
Targeting angiogenesis in biliary tract cancers: An open option
Valeria Simone,Oronzo Brunetti,Luigi Lupo,Mario Testini,Eugenio Maiorano,Michele Simone,Vito Longo,Christian Rolfo,Marc Peeters,Aldo Scarpa,Amalia Azzariti,Antonio Russo,Domenico Ribatti,Nicola Silvestris +13 more
TL;DR: Both the pathogenic mechanisms of BTCs focused on angiogenesis and the preclinical and clinical data available regarding the use of new anti-angiogenic drugs in these malignancies are evaluated.